Ascorbic acid, or vitamin C, is a primary antioxidant in plasma and within cells, but it can also interact with the plasma membrane by donating electrons to the ␣-tocopheroxyl radical and a trans-plasma membrane oxidoreductase activity. Ascorbate-derived reducing capacity is thus transmitted both into and across the plasma membrane. Recycling of ␣-tocopherol by ascorbate helps to protect membrane lipids from peroxidation. However, neither the mechanism nor function of the ascorbate-dependent oxidoreductase activity is known. This activity has typically been studied using extracellular ferricyanide as an electron acceptor. Whereas an NADH:ferricyanide reductase activity is evident in open membranes, ascorbate is the preferred electron donor within cells. The oxidoreductase may be a single membrane-spanning protein or may only partially span the membrane as part of a trans-membrane electron transport chain composed of a cytochrome or even hydrophobic antioxidants such as ␣-tocopherol or ubiquinol-10. Further studies are needed to elucidate the structural components, mechanism, and physiological significance of this activity. Proposed functions for the oxidoreductase include stimulation of cell growth, reduction of the ascorbate free radical outside cells, recycling of ␣-tocopherol, reduction of lipid hydroperoxides, and reduction of ferric iron prior to iron uptake by a transferrin-independent pathway.-May, J. M. Is ascorbic acid an antioxidant for the plasma membrane? FASEB J. 13, 995-1006 (1999) 
Ascorbic acid, or vitamin C, has the potential to protect both cytosolic and membrane components of cells from oxidant damage. In the cytosol, ascorbate acts as a primary antioxidant to scavenge free radical species that are generated as by-products of cellular metabolism. For cellular membranes, it may play an indirect antioxidant role to reduce the ␣-tocopheroxyl radical to ␣-tocopherol. Recycling of ␣-tocopherol by ascorbate has been demonstrated in liposomes and cellular organelles (1, 2) . Recent evidence suggests that ascorbate also spares and probably recycles ␣-tocopherol in erythrocyte membranes (3) and intact erythrocytes (4) . The erythrocyte results indicate that ascorbate can interact directly with the plasma membrane as an antioxidant. It can also donate electrons to a trans-plasma membrane electron transfer activity in erythrocytes (5, 6) and nucleated cells (7) . The scope of ascorbate interaction with both plant and mammalian plasma membranes has been reviewed (8) , so this discussion will focus primarily on the ability of the vitamin to contribute electrons for transfer into and across the plasma membrane of mammalian cells.
Ascorbate can donate either one or two electrons in redox reactions ( Fig. 1) . At physiological pH, more than 99% of ascorbate is in the monoanion form (carbon-3 hydroxyl pK a ϭ 4.2). Loss of the first electron results in the ascorbate free radical (AFR) 2 (1). The AFR, although a stronger reducing agent than ascorbate (9) , is stabilized by resonance on the three-ring oxygens and is not very reactive (10) . Mild oxidants such as ferricyanide (11) and EDTA(Fe 3ϩ ) (12) can remove a second electron and convert the AFR to dehydroascorbic acid (DHA). However, in the absence of such oxidants, the predominant reaction of the AFR is disproportionate to ascorbate and DHA, with a second order rate constant of 10 5 M -1 s -1 at pH 7.0 (10). DHA is unstable at physiological pH, with a half-life of ϳ6 min (13) . Unless reduced back to ascorbate, it undergoes irreversible ring opening to form 2,3-diketo-1-gulonic acid (Fig. 1 ). Based on these considerations, recycling at the AFR stage may have advantages for the ascorbate economy of the cell. The tendency of ascorbate to participate in oneelectron interactions also fits well with its ability to transfer electrons into and across the plasma mem-brane. For example, a one-electron transfer has been proposed to explain reduction of the ␣-tocopheroxyl radical by ascorbate (14) . Electron transfer across the plasma membrane has typically been measured by tracking the reduction of ferricyanide (15) . Both ferricyanide and its one-electron reduced form, ferrocyanide ( Fig. 2) , are large, negatively charged molecules that do not cross the plasma membrane (16) . The rate of extracellular ferricyanide reduction is readily measured spectrophotometrically by following either the loss of ferricyanide (15) or the appearance of ferrocyanide (17) . Although documented in all cells in which it has been sought (18) , ferricyanide reduction has probably been most studied in human erythrocytes. These cells lack intracellular membranes and organelles, and thus offer a simple one-compartment system for study.
Ferricyanide reduction by intact erythrocytes is associated with increased intracellular ATP generation (15) , no change in oxygen consumption (15) , and proton movement out of the cells (19) . The latter likely reflects an attempt of the cell to avoid ferricyanide-induced pH gradients across the cell membrane (20) . The identity of the natural electron donor(s) for this activity has long been a subject of interest (18) . Early studies in ghost membranes suggested that NADH is the electron donor to this activity (21, 22) . The possibility that ascorbate might also serve as a donor derives from the studies of Orringer and Roer (23) , who first showed that addition of DHA to human erythrocytes enhances reduction of extracellular ferricyanide. In their experiments, ferricyanide reduction in erythrocytes was saturable with increasing concentrations of added DHA and was evident in resealed ghosts containing an ascorbate regeneration system. These authors presented a model involving uptake of DHA, intracellular reduction to ascorbate, efflux of ascorbate out of the cells, and direct reduction of extracellular ferricyanide by ascorbate. The ability of DHA to enhance extracellular ferricyanide reduction was confirmed in liver (24) and erythrocytes (5) . In the erythrocyte studies, Schipfer et al. (5) also reported a saturable process with respect to both DHA and ferricyanide, and provided evidence that ferricyanide is reduced by intracellular rather than extracellular ascorbate. The latter derives from the finding that medium obtained from cells incubated with increasing amounts of DHA supports little or no ferricyanide reduction. They also found DHA-induced ferricyanide reduction in intact cells to be inhibited 25% by p-chloromercuribenzene sulfonic acid (PCMBS), a slowly penetrating sulfhydryl reagent. These results indicate that ascorbate-dependent ferricyanide reduction is mediated by a transmembrane process that likely involves a protein. Subsequent reports in the last several years have extended the initial studies and generated additional questions and controversies.
RECENT RESULTS: THE ROLE OF INTRACELLULAR ASCORBATE IN EXTRACELLULAR FERRICYANIDE REDUCTION

Uptake and recycling of DHA and ascorbic acid
The most likely mechanism by which cells can use added DHA to reduce extracellular ferricyanide is depicted in Fig. 3 . The first step involves uptake of DHA across the plasma membrane. Despite the term 'acid' in its common name, DHA is uncharged at physiological pH (Fig. 1 ). This lack of charge increases its ability to diffuse across the plasma mem- (25) showed by direct ascorbate measurements that K562 erythroleukemic cells were able to convert added DHA to ascorbate. However, because ascorbate-dependent ferricyanide reduction was insensitive to cytochalasin B, a specific inhibitor of the glucose transport protein (26) , they concluded that DHA entered the cells by diffusion. It is clear from more recent studies that DHA does enter cells by facilitated diffusion on the glucose transporter. Vera and colleagues reported that Xenopus laevis oocytes, which lack glucose transporters, do not transport DHA (27) . When mRNA from any of several transporter subtypes is microinjected into oocytes, they develop the ability to transport DHA, but not ascorbate. Two subsequent studies in HL-60 cells have confirmed that DHA enters on the glucose transporter (28, 29) . Dependence on the glucose transporter is more difficult to demonstrate in a cell such as the human erythrocyte, which has a high density of transporter protein (30) . For example, Himmelreich and Kuchel (31) failed to detect inhibition of ferricyanide reduction by the transport inhibitors phloretin and cytochalasin B or glucose itself. However, their experiments were carried out for as long as an hour at 37°C, conditions under which glucose is equilibrated across the membrane even in the presence of strong transport inhibition. We were able to show that cytochalasin B inhibits [ 14 C]DHA uptake by erythrocytes (6), but it was necessary to measure transport at 23°C and use short time points to assess initial rates of uptake (i.e., 30 s or less). There may be an additional route of DHA uptake and reduction by erythrocytes not depicted in Fig. 3 . In their nuclear magnetic resonance (NMR) studies of 13 C-labeled DHA uptake by erythrocytes, Himmelreich et al. (32) found DHA reduction to be so rapid and sensitive to metabolic interference that they hypothesized a novel transport mechanism in which DHA is reduced by NADH during its transfer across the membrane. Once inside cells, DHA is very rapidly reduced to ascorbate (Fig. 3) , either directly by GSH (33) or in reactions catalyzed by thioredoxin reductase (4, 34) or glutaredoxin (35) . NADH-dependent mechanisms may also contribute (23, 28) .
Ascorbate itself, probably because of its negative charge, is a very poor substrate for the glucose transporter and exits cells slowly (36) . Ascorbate concentrations in many cells are in the low millimolar range (37) , despite plasma concentrations of 40 -60 M in unsupplemented individuals (38) . Such accumulation of ascorbate against a concentration gradient appears to be due to the action of an energy-and sodium-dependent transport protein (37) . Human erythrocytes appear to lack such a transporter, since plasma and intracellular ascorbate concentrations are the same (38, 39) . Nonetheless, through uptake of DHA and conversion to ascorbate, even erythrocytes can generate intracellular ascorbate concentrations as high as 1-2 mM and maintain them for more than an hour of incubation at 37°C (39) .
Ascorbate as a substrate for a trans-plasma membrane oxidoreductase
If intracellular ascorbate can donate electrons to a trans-plasma membrane oxidoreductase activity, the question arises as to the relative importance of ascorbate compared with other potential electron donors. In intact erythrocytes, we found physiological intracellular concentrations of ascorbate to contribute as much as two-thirds of the basal rate of ferricyanide reduction (6) . To determine the response to decreased intracellular ascorbate, endogenous erythrocyte ascorbate was depleted using the nitroxide free radical Tempol (2,2,6,6,-tetramethyl-4-hydroxypiperidine-N-oxyl), which enters cells and oxidizes ascorbate to DHA (33) . Some of this DHA effluxes from the cells and can be removed by centrifugation washes. Three such Tempol treatments of erythrocytes deplete ascorbate by ϳ80%, without affecting GSH or ␣-tocopherol (40) . Cells depleted of ascorbate in this manner had only about one-third the basal rate of ferricyanide reduction seen in control cells (6) . A preference for ascorbate over NADH was also evident in both resealed and open erythrocyte ghosts. In erythrocyte ghosts that were resealed to contain 400 M concentrations of either NADH or ascorbate, ascorbate-loaded ghosts had about twice the ferricyanide-reducing capacity as the NADH-loaded ghosts (41) . Further, open erythrocyte ghost membranes were able to catalyze reduction of nitroblue tetrazolium with ascorbate as the electron donor at almost twice the rate observed with NADH (41) . Cells that can concentrate ascorbate may depend even more on ascorbate as a donor for trans-plasma membrane electron transfer. Human HL-60 cells (28) and U-937 cells ( J. M. May, unpublished data), when cultured in ascorbate-deficient media, contain no endogenous ascorbate. Loading of these cells with DHA to achieve intracellular ascorbate concentrations of 4 -6 mM increases ferricyanide reduction by five-to eightfold. Freshly prepared human monocytes, from which U-937 cells are thought to derive (42) , have intracellular ascorbate concentrations of ϳ6 -8 mM (43) . Therefore, ascorbate may be even more important as an electron donor to this trans-plasma membrane electron transfer activity in nucleated cells than in erythrocytes.
As noted previously, early studies showed saturable ferricyanide reduction in erythrocytes loaded with increasing concentrations of DHA. Although kinetic values were not reported, half-maximal ferricyanide reduction occurred at initial extracellular DHA concentrations of less than 100 M (5, 23). This contrasts with ascorbate accumulation in erythrocytes, which is half-maximal after loading with 400 M extracellular DHA (39) . Together, these results suggest that the trans-plasma membrane reductase and not the intracellular ascorbate concentration is ratelimiting for ferricyanide reduction. In other cells, direct ascorbate measurements prior to assessment of ferricyanide reduction have confirmed this hypothesis. In HL-60 cells (28) and in U-937 cells ( J. M. May, unpublished data), rates of extracellular ferricyanide reduction were half-maximal at intracellular ascorbate concentrations of 0.6 and 0.8 mM, respectively. These values are well below the ascorbate concentration measured in freshly prepared monocytes. However, decreases in intracellular ascorbate due to oxidant stress, ascorbate secretion (44 -46) , or loss during culture in ascorbate-deficient media might limit the capacity of the oxidoreductase.
Ferricyanide, the usual artificial electron acceptor for the trans-plasma membrane oxidoreductase, necessarily participates in one-electron transfers. Thus the question arises as to whether the oxidoreductase activity removes one electron at a time from the intracellular electron donor. This can be tested with ascorbate, which is readily detected in its one-electron oxidized form as the AFR. We found that extracellular ferricyanide does generate the AFR in human erythrocytes (Fig. 3) , whereas ascorbate oxidase fails to do so under the same conditions (47) . Ascorbate oxidase produces the AFR in a direct reaction, with subsequent dismutation of two AFR molecules to one molecule each of DHA and ascorbate (48) . Since ascorbate oxidase is restricted to the extracellular space, its failure to generate an AFR signal in intact erythrocytes suggests that the signal observed with ferricyanide was from intracellular ascorbate and not from oxidation of ascorbate that had leaked out of the cells. The ferricyanide-induced AFR signal in intact erythrocytes is also not due to participation of the AFR as an intermediate in intracellular DHA reduction, since DHA added to erythrocytes does not generate an AFR signal (47) . Rather, as depicted in Fig. 3 , DHA reduction likely involves a two-electron substitution mechanism for GSH alone (49) and for the reactions catalyzed by glutaredoxin (35) and thioredoxin reductase (34) .
There are several possible reactions of the AFR generated by ferricyanide in erythrocytes, which are schematized in Fig. 4 . Since the AFR carries a negative charge at physiological pH (50) , it is unlikely to efflux from the cells at an appreciable rate. The AFR could 1) donate another electron to the trans-membrane reductase, 2) dismutate to DHA and ascorbate, or 3) be reduced back to ascorbate by an AFR reductase. The first two reactions would generate DHA, which could either efflux from cells or undergo reduction back to ascorbate, as depicted in Fig. 3 . Ferricyanide does generate intracellular DHA from ascorbate, which we have detected as efflux of [ 14 C]DHA on the glucose transporter (6) and which Himmelreich and Kuchel (32) have measured directly in ferricyanide-treated erythrocytes. Nonetheless, direct recycling of the AFR may also occur. Open erythrocyte membranes show NADH-dependent AFR reductase activity (51) . Such ghosts contain both cytochrome b 5 and cytochrome b 5 reductase (52, 53) , and the latter appears to be identical to microsomal cytochrome b 5 reductase in other cell types (54) . The microsomal cytochrome b 5 reductase system has long been known to carry out NADHdependent reduction of the AFR (55) . Therefore, reduction of the AFR immediately after its generation (Fig. 4) is plausible and makes sense in the ascorbate economy of the cell, since there would be less flux down the pathway toward irreversible ring opening of DHA. The question then arises as to the relationship, if any, between the trans-plasma mem- brane oxidoreductase and the putative AFR reductase (indicated by the question mark in Fig. 4) . This question will be addressed next.
CONTROVERSIES AND UNRESOLVED QUESTIONS: MECHANISM AND FUNCTION OF THE OXIDOREDUCTASE
Possible mechanisms of the ascorbate-dependent oxidoreductase activity
Is it a cofactor-dependent, trans-membrane NADHdependent ferricyanide reductase?
As noted, ferricyanide-induced electron transfer in intact cells is thought to be mediated by a transplasma membrane oxidoreductase protein that uses intracellular NADH (5, 18) or ascorbate (6) as electron donors (Fig. 5, mechanism 1) . A transplasma membrane orientation of the erythrocyte ascorbate-dependent enzyme is also supported by the observations that its activity is inhibited by the poorly permeant protein reagents (5, 56) and that external ferricyanide is reduced by internal ascorbate in tightly resealed ghosts (23, 41, 57) . Such a trans-plasma membrane activity requires an exofacial site reactive with ferricyanide and an endofacial site available to accept electrons from cytoplasmic donors (18) . Whereas erythrocyte cytochrome b 5 reductase may be a major ferricyanide reductase in open membranes, it has a cytoplasmic orientation (18, 58) . The same argument holds for cytochrome b 5 itself (18, 59) and for cytochrome c reductase activity (60) . Much of the latter activity may be due to the cytochrome b 5 system (18), since cytochrome c can be reduced by the combined action of cytochrome b 5 and cytochrome b 5 reductase (53) . A cytoplasmic orientation does not necessarily rule out participation in a trans-plasma membrane process, but it does require involvement of other membrane proteins or transfer agents, as discussed below.
A presumed membrane-spanning NADH-dependent ferricyanide reductase has been purified from erythrocyte ghosts by Wang and Alaupovic (21) . The monomeric form of this protein differs from cytochrome b 5 reductase with respect to size, kinetic behavior, cofactor dependence, and membrane orientation. With an apparent molecular mass of 40 kDa, it is ϳ10% larger than the erythrocyte cytochrome b 5 reductase (53) . It has a lower affinity for NADH (20 M) than the membrane-bound cytochrome b 5 reductase (0.6 M) (53) and also differs from the latter enzyme in showing both substrate and product inhibition. A trans-plasma membrane orientation is suggested by the presence of ϳ6% by weight carbohydrate. However, the location of the NADH binding site for this enzyme has not been established, so that it could correspond to a cell surface NADH:ferricyanide reductase activity that has been reported in erythrocytes (56) and other cells (61) . It is also not known whether this enzyme can use ascorbate as an electron acceptor. Nonetheless, it is plausible that the enzyme purified by Wang and Alaupovic corresponds to the trans-plasma membrane NADH-dependent ferricyanide reductase activity later characterized by Grebing et al. (56) .
Is it an AFR reductase?
The trans-plasma membrane ferricyanide reductase could also function by a mechanism analogous to that of the chromaffin granule system in adrenomedullary cells. These granules contain high concentrations of ascorbate (22 mM) (62) , which serves as a cofactor for hydroxylation of dopamine by dopamine ␤-hydroxylase to generate norepinephrine (46) . The hydroxylation step is a one-electron transfer that generates the AFR. The AFR is reduced back to ascorbate by a trans-membrane electron carrier that has been identified as cytochrome b 561 (63, 64) . This reaction is driven by an inward proton gradient that is generated by an H ϩ -ATPase in the granule membrane (46) . The protons are required for reduction of the AFR and serve to balance the influx of electrons via the cytochrome. This system, which is shown in Fig. 6 , has the same orientation as the plasma membrane system if one considers that the granule interior corresponds to the extracellular space in the model of Fig. 3 . Although erythrocyte membranes do not contain cytochrome b 561 , the cytochrome b 5 /cytochrome b 5 reductase pair could perform this function, with the caveat that other membrane elements are also required. Erythrocyte membranes do contain an additional cytochrome, cytochrome P-420, which presumably is derived from cytochrome P-450 (52, 65) . Whether this cytochrome is involved in trans-plasma membrane electron transfer is unknown. Another issue raised by consideration of the chromaffin granule AFR reductase is the necessary coupling between electron transfer by the trans-plasma membrane system and proton export. Since the initial results of Dormandy and Zarday (19) , which documented proton export from human erythrocytes during ferricyanide reduction, there has been little consideration of whether intracellular pH changes occur, whether they limit ferricyanide reduction, or whether electron and proton efflux are coupled. Again, by analogy to the chromaffin granule system, a pH gradient maintained by an H ϩ -ATPase may be essential to drive any trans-membrane reduction of the AFR by intracellular ascorbate.
An AFR reductase activity has been reported for human erythrocyte membranes that appears to span the cell membrane, since it was latent in both resealed ghosts and inside-out resealed ghosts (51). Schweinzer and Goldenberg (7, 25) later described a cell surface AFR reductase activity in K562 and U-937 cells that also presumably spans the cell membrane. In this system, ferricyanide is used to generate the AFR from low concentrations of extracellular ascorbate. The AFR is then reduced at the cell surface by an AFR reductase, which obtains electrons from as yet unidentified intracellular donor (Fig. 5, mechanism 2) . The AFR reductase has a high affinity for the AFR, with an apparent K m in the low picomolar range (7) . It is dependent on the membrane potential (25) , which may reflect the need for proton export (Fig. 6) . It is also inhibited by thenoyltrifluoroacetone (25), a known inhibitor of microsomal NADH-dependent AFR reductase activity (66) . In the natural setting, the AFR would be generated outside cells by oxidants such as superoxide and traces of ferric iron; intracellular NADH or ascorbate would serve as intracellular electron donors. Interpretation of these studies is complicated because ferricyanide is used both to oxidize extracellular ascorbate to the AFR and quantify AFR reduction. Any DHA generated outside the cells will be taken up and converted to ascorbate. Intracellular ascorbate can then serve as a substrate for the transplasma membrane system.
The question of whether the trans-plasma membrane oxidoreductase is an AFR reductase has been addressed by Villalba et al. (67) , with negative results. They reported that purified liver plasma membranes have ferricyanide and AFR reductase activities, but that these differ with regard to sensitivity to detergent extraction, clathrin depletion or inactivation, and to inhibition by wheat germ agglutinin. They concluded that the ferricyanide and AFR reductase activities are not mediated by the same protein in these membranes, although these proteins could form part of an electron transport chain across the plasma membrane.
Is it mediated by hydrophobic antioxidants?
Another possibility is that lipid-soluble antioxidants such as ubiquinol-10, ␣-tocopherol, or ␣-tocopheryl hydroquinone contribute to the trans-membrane electron transfer from intracellular ascorbate to extracellular ferricyanide (or to the AFR). In such a mechanism, one-electron oxidation of the phenolic group of the quinones or ␣-tocopherol generates a phenoxyl radical on the head group; the latter then migrates to the cytoplasmic leaflet of the lipid bilayer and reacts with a reductase or, in the case of ␣-tocopherol, with ascorbate itself (Fig. 5, mechanisms 3,  4) . Sun et al. (68) have shown that the ferricyanide reductase activity of erythrocyte ghosts or hepatocyte plasma membranes is proportional to the content of ubiquinone-10 and ␣-tocopherylquinone, and that this reductase activity is inhibited by ubiquinone analogs. These results prompted the suggestion that ubiquinol/one-10 is involved in trans-plasma membrane electron transfer processes (68) .
More recently, an ubiquinone-10-dependent NADH:AFR reductase activity has been described in purified K562 cell plasma membranes (69) . This activity also parallels the ubiquinone-10 content of the membranes and is inhibited by capsaicin and dicumarol, which are inhibitors of ubiquinone-10-dependent electron transport (69) . Significantly, this NADH:ubiquinone-10 reductase has an internal protein sequence identical to that of cytochrome b 5 reductase (70, 71) . It has been suggested that ubiquinol/one-10 serves as an electron transfer agent be- tween the external cell surface and the inward-facing cytochrome b 5 reductase and that this could account for stabilization of extracellular ascorbate by K562 cells (69) . In this mechanism, ubiquinol-10 donates one or two electrons at the cell surface to reduce the AFR to ascorbate. Either the quinone or radical form then migrates across the bilayer to be reduced by cytochrome b 5 reductase, using NADH-derived electrons. However, the notion that a long-chain hydrophobic quinone such as ubiquione/ol-10 can move efficiently across the membrane bilayer is controversial. Initial studies using dithionite reduction of ferricyanide trapped within liposomes showed that long-chain quinones were more effective electron transfer agents than were short-chain forms (72, 73) . However, when less hydrophobic reducing agents such as ascorbate (73, 74) and sodium borohydride (75) are used, there is very little tendency for transbilayer electron transfer by long-chain quinones or semiquinones. Long-chain quinones are viewed as restricted to the center of the bilayer and incapable of movement to either membrane face (75) . If ubiquinol/one-10 is restricted to the center of the bilayer, it would not be able to donate electrons to ascorbate. Reduction of the AFR would then require a link to the membrane surface. Ubiquinol-10 efficiently reduces ␣-tocopherol in lipid bilayers (76) ; since the chromanol ring of ␣-tocopherol does reside at the level of the phospholipid polar headgroups (9), both hydrophobic antioxidants could work together (Fig. 5, mechanism 3) .
It is also possible that ␣-tocopherol could work independently of ubiquinol/one-10 to transfer electrons across the membrane bilayer (Fig. 5 , mechanism 4), especially since ␣-tocopherol is much more abundant than ubiquinol/one-10 in membranes (68) . It has been shown that ␣-tocopherol can transfer electrons from ascorbate trapped within liposomes to extravesicular ferricyanide (74) . We recently confirmed this reaction and found that it was associated with sparing of ␣-tocopherol and protection against lipid hydroperoxide formation (77). Ilani and Krakover also demonstrated that the rate of reaction of ␣-tocopherol at the lipid-water interface was much slower than its reaction in solution (74) . Thus, trans-membrane electron transfer by ␣-tocopherol appears to be limited both by its shuttle frequency across the bilayer and by the rates of redox reactions at the lipid-water interface on either side of the bilayer. We have reported that the ability of ascorbate in tightly sealed human erythrocyte ghosts to reduce extravesicular ferricyanide parallels the membrane content of ␣-tocopherol (57). In the latter studies, ferricyanide reduction by resealed ghosts was increased by addition of exogenous ␣-tocopherol during ghost preparation and decreased by removal of endogenous ␣-tocopherol. On the other hand, supplementation of ␣-tocopherol in the culture medium of HL-60 cells had no effect on their ability to reduce ferricyanide nor did ␣-tocopherol affect the enhanced rates of ferricyanide reduction in ascorbate-supplemented cells (28) . Whereas ␣-tocopherol-mediated electron transfer is plausible from in vitro studies, it may not be present in all cells or may require additional co-factors not present in cultured cells.
Does it involve protein sulfhydryl groups?
Trans-membrane electron transfer by sulfhydryl groups on thiol-rich trans-plasma membrane proteins has also been suggested (Fig. 5, mechanism 5 ). Using the technique of spin-echo 1 H-NMR spectroscopy to detect GSH in human erythrocytes, Reglinski et al. (78) found that incubation of intact erythrocytes with 0.5-1 mM 5, 5Ј-dithiobis(2-nitrobenzoic acid) (DTNB) caused depletion of intracellular GSH by as much as 30%. DTNB, which does not penetrate the erythrocyte membrane, generates a mixed disulfide between a surface-exposed protein sulfhydryl and 5-thio-2-nitrobenzoic acid. This oxidant stress is somehow transduced across the cell membrane to form mixed disulfides between intracellular GSH and protein sulfhydryls. Ciriolo et al. (79) have used the same technique to confirm the initial DTNB results and to show that 0.5 mM GSH (but not cysteine) added externally to erythrocytes increases intracellular GSH concentrations. The latter effect was considered to be due to transfer of the reducing power of GSH across the plasma membrane to reduce mixed disulfides of GSH with intracellular proteins. However, external GSH did not reverse DTNB-induced depletion in intracellular GSH. Since GSH can reduce mixed disulfides of 2-nitro-5-thiobenzoic acid and GSH (80) , it may be able to do so for mixed disulfides of 2-nitro-5-thiobenzoic acid and protein thiols. If so, then either the 2-nitro-5-thiobenzoic acid-protein thiol conjugates on the cell surface proteins are not accessible to GSH or the mechanisms of DTNB and GSH effects are different. Whether either phenomenon is related to ascorbatedependent ferricyanide reduction is unknown. By oxidizing cell surface thiols, ferricyanide could generate a trans-membrane oxidant stress in a manner analogous to that produced by DTNB. It has been shown that PCMBS decreases ascorbate-dependent ferricyanide reduction by both erythrocytes (5) and HL-60 cells (28) . On the other hand, we found that ferricyanide treatment of glucose-depleted erythrocytes increased, rather than decreased, their content of GSH by 17% (47) . Despite the discrepancies, these results suggest that membrane thiols should receive further study for involvement in ascorbatedependent, trans-membrane electron transfer.
Possible cellular functions of the oxidoreductase
Several roles for the trans-plasma membrane oxidoreductase activity have been proposed, including function as an AFR reductase, an ␣-tocopheroxyl or hydroperoxyl radical reductase, a lipid hydroperoxide reductase, a stimulant of cell growth, and a ferric iron reductase to facilitate transferrin-independent iron uptake.
Function as an AFR reductase
Function of the trans-plasma membrane oxidoreductase as a cell surface AFR reductase would provide a mechanism for cells to efficiently regenerate extracellular ascorbate from the AFR. Since most cells maintain a steep concentration gradient of ascorbate across their plasma membranes (37) , release of ascorbate into plasma and the interstitium is probably minimal. Exceptions are release of ascorbate stored in secretory granules from chromaffin cells (45, 46 ) and brain cells (44) . A cell surface AFR reductase that uses electrons from either NADH or ascorbate might thus play a role in maintaining critical extracellular stores of the vitamin. Extracellular recycling of ascorbate by white and red cells would be especially important in areas of inflammation or atherosclerosis in the vascular bed, since such ascorbate could recycle ␣-tocopherol and prevent lipid peroxidation in LDL and lipids (81) .
A cell surface NADH:AFR reductase activity has been proposed to maintain ascorbate concentrations outside of cells in culture (69, 82) . Prevention of extracellular ascorbate loss is stimulated by growth factors (83), addition of lactate (82) , and increases in the cellular content of cyclic AMP (84) . It is inhibited by lectins that are known to bind to cell surface carbohydrate (82) . However, these studies rely on an indirect assay, which does not measure either extracellular AFR reduction or intracellular NADH oxidation. Goldenberg and colleagues (85) have pointed out that other mechanisms could also preserve ascorbate outside cells. For example, a cell surface DHA reductase activity has been reported in K562 cells (86) , and chelation of trace metals by proteins released from cells could account for the observed preservation of ascorbate (85) . Secretion of ascorbate from specialized cells might also contribute. Additional studies are needed to document the presence, capacity, and physiological significance of cell surface AFR reduction. Nonetheless, a cell surface AFR reductase would provide an efficient mechanism for regenerating extracellular ascorbate. If coupled to an energy-generating step such as an H ϩ -ATPase, as in the chromaffin granule system (Fig. 6 ), ascorbate could serve as a donor in addition to NADH.
Function as a lipid hydroperoxyl or ␣-tocopheroxyl free radical reductase
The trans-plasma membrane oxidoreductase could transfer ascorbate-derived electrons into as well as across the plasma membrane. In the lipid bilayer, electrons from ascorbate or even the AFR could help to reduce lipid hydroperoxyl radicals or recycle the one-electron-oxidized forms of lipid-soluble antioxidants. Based on oxidation reduction potentials, neither ascorbate nor the AFR can reduce ubiquinone-10 nor its semiquinone (9) . Moreover, a ubiquinol-10 reductase has been proposed to reduce the AFR to ascorbate (69), and not the converse. Whether ascorbate or the AFR can reduce lipid hydroperoxyl radicals is unknown, although a consideration of the redox potentials involved suggests that this reaction may be possible (9) . Ascorbate is well known to recycle the ␣-tocopheroxyl radical. It is also possible that an intervening enzyme or carrier in the cell membrane enhances the ability of ascorbate at the cytoplasmic membrane face to reduce the ␣-tocopheroxyl radical within the lipid bilayer. To implicate the ascorbate-or NADH-dependent oxidoreductase activity in such recycling, additional studies are needed to show that ␣-tocopherol recycling depends on the enzyme activity.
An NADH-dependent reductase activity of human erythrocyte membranes has been reported to reduce cumene and linoleoyl hydroperoxides to their alcohol forms (87) . It was suggested that this activity might correspond to the NADH-dependent ferricyanide reductase activity (87) , which could implicate ascorbate as an electron donor. Ascorbate is unable to directly reduce lipid hydroperoxides (88), but it might be able to do so indirectly by donating electrons to an enzyme with that capability. Such an activity could also serve to enhance the antioxidant function of ␣-tocopherol, which reduces lipid hydroperoxyl radicals to hydroperoxides. Hydroperoxides generated by ␣-tocopherol will accumulate unless reduced or removed from the membrane (89) . In this mechanism, ascorbate donates electrons to the hydroperoxide reductase, which then detoxifies hydroperoxides generated by the action of ␣-tocopherol. This would complement the ability of ascorbate to reduce the ␣-tocopheroxyl radical. However, the presence of such an NADH-dependent membranebound lipid hydroperoxide reductase has not been confirmed nor has ascorbate been studied as an electron donor. To be of physiological relevance, this activity would also have to reduce lipid hydroperoxides present in phospholipids, as has been done for phospholipid hydroperoxide glutathione peroxidase (90) .
Stimulation of cell growth and differentiation
The trans-plasma membrane oxidoreductase that uses ferricyanide as an external electron acceptor may be involved in stimulation of cell growth and differentiation. As reviewed by Crane et al. (91) , this hypothesis is based on the finding that ferricyanide added to serum-deprived tumor cells in culture enhances cell division and differentiation (92) . Involvement of an ascorbate-dependent, trans-plasma membrane oxidoreductase in ferricyanide-induced cell division has little support. As reviewed by Navas et al. (8) , ascorbate, probably through its facilitation of collagen synthesis, can stimulate cell growth. However, since cultured cells generally lack ascorbate (28), there seems to be little role for ascorbate in the ferricyanide effect in cultured cells.
Function as part of a transferrin-independent iron uptake system
It is possible that ascorbate, through the activity of a trans-plasma membrane enzyme, could provide electrons for transferrin-independent reduction of ferric iron and thus facilitate iron uptake by cells. This function was postulated many years ago for both ascorbate (23) and a trans-plasma membrane enzyme (5). Transferrin-independent iron uptake has been documented in a variety of cell types (93, 94) and may complement transferrin-dependent mechanisms. Transferrin-independent iron uptake is thought to involve binding of ferric iron to the cell surface (95) , reduction of the ferric to ferrous iron, and uptake of the latter (96) . Ferricyanide has been shown to inhibit uptake of radiolabeled iron from ferric chelates in K562 cells (97) and Caco-2 intestinal cells (98) . The effect of ferricyanide brings up the question of whether the trans-membrane oxidoreductase is involved and whether intracellular reducing equivalents from ascorbate can reduce ferric to ferrous iron before uptake of the latter. Han et al. (98) found that increasing the intracellular concentration of ascorbate by loading Caco-2 cells with DHA enhanced radiolabled iron uptake. However, since this effect was abolished by inclusion of ascorbate oxidase, it may have been due to direct reduction of ferric iron by ascorbate that had leaked from the cells. Our recent results in U-937 cells favor the latter explanation (99) . Whereas ascorbateloaded cells had enhanced uptake of 55 Fe and reduction of extracellular ferric citrate, both activities were abolished by ascorbate oxidase. Further, ascorbate oxidase was without effect on ascorbate-dependent ferricyanide reduction, which strongly argues against involvement trans-plasma membrane oxidoreductase in iron uptake.
FUTURE DIRECTIONS: ELUCIDATION OF THE STRUCTURE, FUNCTION, AND REGULATION OF A TRANS-PLASMA MEMBRANE OXIDOREDUCTASE
The molecular structure of the putative trans-plasma membrane oxidoreductase, whether ascorbate-dependent or -independent, has not been established. Early attempts at purification and amino acid analysis of such a protein from human erythrocytes (21) have not been confirmed or extended with molecular techniques. Complicating purification of such a protein is its hydrophobicity, and whether it might require a cofactor, such as a cytochrome or a lipidsoluble antioxidant. Ferricyanide reductase activity from Ehrlich ascites cell plasma membranes, which appears to be trans-membrane in orientation, has been reconstituted into phospholipid vesicles (100). However, this activity was not shown to span the lipid bilayer and its ascorbate dependence was not tested, since NADH was used as substrate.
Neither the function of the trans-membrane oxidoreductase nor the role that intracellular ascorbate might play in that function has been established. Available evidence narrows the function of this activity to two major areas: enhancement of cell growth and differentiation and an antioxidant role to protect the cell membrane or to recycle extracellular ascorbate. Regarding the latter, further studies are needed to define the role of intracellular ascorbate as a natural substrate, to establish whether intracellular ascorbate can reduce extracellular AFR, and to determine whether the system can serve in some manner to protect the cell membrane from extracellular oxidant stress in areas of inflammation.
There is no evidence for either pre-or posttranslational regulation of the trans-plasma membrane oxidoreductase. On the other hand, it is intriguing that ferricyanide reduction varies greatly between blood cells obtained from different donors (31) . Whereas much of this variance appears to relate simply to different intracellular ascorbate concentrations (31), the possibility of genetic variation must be considered. Defining the identity, mechanism, and function of the oxidoreductase will provide clues as to how it might be regulated.
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